These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20425440)

  • 1. Lenalidomide in myelodysplastic syndromes: where do we go from here?
    Sirulnik LA; Stone RM
    Curr Hematol Malig Rep; 2008 Jan; 3(1):5-9. PubMed ID: 20425440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
    Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
    Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
    Voutsadakis IA; Cairoli A
    Leuk Lymphoma; 2012 May; 53(5):779-88. PubMed ID: 21955212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.
    Sekeres MA; Maciejewski JP; Giagounidis AA; Wride K; Knight R; Raza A; List AF
    J Clin Oncol; 2008 Dec; 26(36):5943-9. PubMed ID: 19018091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of lenalidomide in the management of myelodysplasia with del 5q.
    Kelaidi C; Eclache V; Fenaux P
    Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
    List AF; Baker AF; Green S; Bellamy W
    Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
    Komrokji RS; List AF
    Ann Oncol; 2016 Jan; 27(1):62-8. PubMed ID: 26504152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent malignant stem cells in del(5q) myelodysplasia in remission.
    Tehranchi R; Woll PS; Anderson K; Buza-Vidas N; Mizukami T; Mead AJ; Astrand-Grundström I; Strömbeck B; Horvat A; Ferry H; Dhanda RS; Hast R; Rydén T; Vyas P; Göhring G; Schlegelberger B; Johansson B; Hellström-Lindberg E; List A; Nilsson L; Jacobsen SE
    N Engl J Med; 2010 Sep; 363(11):1025-37. PubMed ID: 20825315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide in del 5q MDS: responses and side effects revisited.
    Tiu RV; Sekeres MA
    Leuk Res; 2011 Nov; 35(11):1440-1. PubMed ID: 21764127
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
    Ximeri M; Galanopoulos A; Klaus M; Parcharidou A; Giannikou K; Psyllaki M; Symeonidis A; Pappa V; Kartasis Z; Liapi D; Hatzimichael E; Kokoris S; Korkolopoulou P; Sambani C; Pontikoglou C; Papadaki HA;
    Haematologica; 2010 Mar; 95(3):406-14. PubMed ID: 19773257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.
    Giagounidis AA; Kulasekararaj A; Germing U; Radkowski R; Haase S; Petersen P; Göhring G; Büsche G; Aul C; Mufti GJ; Platzbecker U
    Leukemia; 2012 Apr; 26(4):855-8. PubMed ID: 21960245
    [No Abstract]   [Full Text] [Related]  

  • 13. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Stahl M; Zeidan AM
    Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.
    Giagounidis A; Fenaux P; Mufti GJ; Muus P; Platzbecker U; Sanz G; Cripe L; Von Lilienfeld-Toal M; Wells RA
    Ann Hematol; 2008 May; 87(5):345-52. PubMed ID: 18265982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of lenalidomide in the treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
    Breccia M; Cannella L; Latagliata R; Nanni M; Santopietro M; Loglisci G; Ferretti A; Barzotti R; Oliva EN; Alimena G
    Leuk Res; 2011 Jun; 35(6):e69-70. PubMed ID: 21232796
    [No Abstract]   [Full Text] [Related]  

  • 17. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C; Carter T; Schafer P; Chopra R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
    Talati C; Sallman D; List A
    Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.
    List AF
    Cancer Control; 2006 Dec; 13 Suppl():12-6. PubMed ID: 17242662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.
    Abouyahya I; Alhan C; Westers TM; te Boekhorst PA; Kappers-Klunne MC; Coenen JL; Heyning FH; Huls GA; de Wolf JT; Imholz AL; Koene HR; Veth G; de Kruijf EJ; Muus P; Planken EV; Segeren CM; Vasmel WL; van der Velden AM; Velders GA; Koedam J; Ossenkoppele GJ; van de Loosdrecht AA
    Leuk Lymphoma; 2013 Apr; 54(4):874-7. PubMed ID: 22971215
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.